6 Phase III: efficacy and safety of oral semaglutide in T2D 6.1 Overview of the PIONEER program (PIONEER 18) The efficacy and safety of oral semaglutide have been extensively evaluated across the continuum of T2D in the phase III PIONEER clinical trial program [39, 61, 62, 76,77,78,79,80,81,82]
Researchers at 23andMe conducted a large-scale genome-wide association study (GWAS) utilizing data from 27,885 individuals who have used GLP-1 medications
The weighted incidence of suicidality was 4.3 and 4.6 for every 1,000 person-years in individuals prescribed GLP-1 receptor agonists and SGLT-2 inhibitors, respectively
By Ginia Bellafante An upgrade transformed the beleaguered virtual assistant into a modern chatbot
Lifestyle Factors No supplement can out-train a bad lifestyle